NYSE · IDXX
Healthcare · Medical - Diagnostics & Research
$510.73
Up+$1.17 (+0.23%)
Updated Sep 16, 2026, 9:27 AM
SID Score
4.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
IDXX closed at $510.73 after 20 trading sessions, down 7.70% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $509.56 | $516.02 | $502.40 | $510.73 | 603.67K |
| Sep 14, 2026 | $510.83 | $515.48 | $505.015 | $509.56 | 454.14K |
| Sep 11, 2026 | $509.88 | $511.15 | $500.61 | $504.70 | 401.63K |
| Sep 10, 2026 | $508.44 | $514.3001 | $504.77 | $506.53 | 422.34K |
| Sep 9, 2026 | $517.00 | $522.49 | $511.16 | $515.15 | 556.5K |
| Sep 8, 2026 | $528.42 | $529.015 | $519.073 | $520.21 | 613.03K |
| Sep 4, 2026 | $522.05 | $536.085 | $522.05 | $535.38 | 407.85K |
| Sep 3, 2026 | $542.02 | $548.85 | $527.74 | $529.29 | 590.42K |
| Sep 2, 2026 | $546.73 | $558.42 | $537.31 | $538.99 | 655.55K |
| Sep 1, 2026 | $555.95 | $555.95 | $541.53 | $545.16 | 458.29K |
| Aug 31, 2026 | $547.68 | $561.24 | $543.60 | $556.69 | 698.43K |
| Aug 28, 2026 | $547.81 | $556.01 | $545.48 | $554.99 | 340.99K |
| Aug 27, 2026 | $549.73 | $553.11 | $542.01 | $545.08 | 340.58K |
| Aug 26, 2026 | $544.13 | $555.705 | $544.13 | $553.44 | 349.44K |
| Aug 25, 2026 | $555.50 | $558.0625 | $549.42 | $550.01 | 385.74K |
| Aug 24, 2026 | $559.21 | $562.19 | $554.23 | $559.51 | 388.93K |
| Aug 21, 2026 | $550.14 | $557.66 | $544.88 | $556.93 | 485.78K |
| Aug 20, 2026 | $562.05 | $563.13 | $543.60 | $545.86 | 610.65K |
| Aug 19, 2026 | $556.78 | $575.56 | $555.00 | $562.20 | 453.65K |
| Aug 18, 2026 | $553.725 | $559.46 | $549.75 | $553.32 | 570.34K |
The latest Smart Investors Daily articles mentioning IDXX.
IDXX research
Company profile and research snapshot.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | Barclays | Overweight | — |
| Aug 5, 2026 | UBS | Neutral | — |
| Aug 5, 2026 | Citigroup | Neutral | — |
| Jul 27, 2026 | UBS | Neutral | — |
| Apr 28, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
Yahoo · Sep 10, 2026
Kingsley exercised options at $114.17 per share before immediately selling at $532.08, capturing a significant gain. His direct stake remains at 9,568 shares worth $5.12 million.
Benzinga · Sep 10, 2026
In a new SEC filing on September 9, it was revealed that Kingsley, Board Member at IDEXX Laboratories (NASDAQ:IDXX), executed a significant exercise of company stock options. What Happened: Disclosed in a Form 4 filing
Yahoo · Sep 10, 2026
Despite trailing the Dow over the past year, IDEXX still has Wall Street on its side, with analysts maintaining a cautiously optimistic view on its future prospects.
Yahoo · Aug 31, 2026
WESTBROOK, Maine, August 31, 2026--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IDXX.
